Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study

Fabian aus dem Siepen,1 Ralf Bauer,1 Matthias Aurich,1 Sebastian J Buss,1 Henning Steen,1 Klaus Altland,2 Hugo A Katus,1 Arnt V Kristen1 1Department of Cardiology, Angiology, and Respiratory Medicine, University Hospital Heidelberg, Heidelberg, Germany; 2Institute of Human Genetics, Justus-Liebig-U...

Full description

Bibliographic Details
Main Authors: aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altl, K, Katus HA, Kristen AV
Format: Article
Language:English
Published: Dove Medical Press 2015-12-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/green-tea-extract-as-a-treatment-for-patients-with-wild-type-transthyr-peer-reviewed-article-DDDT
id doaj-d65b527e6bbc4b60a0aa57b985262063
record_format Article
spelling doaj-d65b527e6bbc4b60a0aa57b9852620632020-11-24T23:48:27ZengDove Medical PressDrug Design, Development and Therapy1177-88812015-12-012015Issue 16319632524858Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational studyaus dem Siepen FBauer RAurich MBuss SJSteen HAltlKKatus HAKristen AVFabian aus dem Siepen,1 Ralf Bauer,1 Matthias Aurich,1 Sebastian J Buss,1 Henning Steen,1 Klaus Altland,2 Hugo A Katus,1 Arnt V Kristen1 1Department of Cardiology, Angiology, and Respiratory Medicine, University Hospital Heidelberg, Heidelberg, Germany; 2Institute of Human Genetics, Justus-Liebig-University, Giessen, Germany Background: Causative treatment of patients with wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is lacking. Recent reports indicate the potential use of epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, to inhibit amyloid fibril formation. We sought to investigate changes of cardiac function and morphology in patients with wtATTR-CM after consumption of green tea extract (GTE). Methods: Twenty-five male patients (71 [64; 80] years) with wtATTR-CM were submitted to clinical examination, echocardiography, cardiac magnetic resonance imaging (cMRI) (n=14), and laboratory testing before and after daily consumption of GTE capsules containing 600 mg epigallocatechin-3-gallate for at least 12 months. Results: A significant decrease of left ventricular (LV) myocardial mass by 6% (196 [100; 247] vs 180 [85; 237] g; P=0.03) by cMRI and total cholesterol by 8.4% (191 [118; 267] vs 173 [106; 287] mg/dL; P=0.006) was observed after a 1-year period of GTE consumption. LV ejection fraction by cMRI (53% [33%; 69%] vs 54% [28%; 71%]; P=0.75), LV wall thickness (17 [13; 21] vs 18 [14; 25] mm; P=0.1), and mitral annular plane systolic excursion (10 [5; 23] vs 8 [4; 13] mm; P=0.3) by echocardiography remained unchanged. Conclusion: This study supports LV mass stabilization in patients with wtATTR-CM consuming GTE potentially indicating amyloid fibril reduction. Keywords: wild-type ATTR, cardiomyopathy, polyphenol, EGCGhttps://www.dovepress.com/green-tea-extract-as-a-treatment-for-patients-with-wild-type-transthyr-peer-reviewed-article-DDDTwildtype-ATTRcardiomyopathypolyphenolEGCG
collection DOAJ
language English
format Article
sources DOAJ
author aus dem Siepen F
Bauer R
Aurich M
Buss SJ
Steen H
Altl
K
Katus HA
Kristen AV
spellingShingle aus dem Siepen F
Bauer R
Aurich M
Buss SJ
Steen H
Altl
K
Katus HA
Kristen AV
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
Drug Design, Development and Therapy
wildtype-ATTR
cardiomyopathy
polyphenol
EGCG
author_facet aus dem Siepen F
Bauer R
Aurich M
Buss SJ
Steen H
Altl
K
Katus HA
Kristen AV
author_sort aus dem Siepen F
title Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
title_short Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
title_full Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
title_fullStr Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
title_full_unstemmed Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
title_sort green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
publisher Dove Medical Press
series Drug Design, Development and Therapy
issn 1177-8881
publishDate 2015-12-01
description Fabian aus dem Siepen,1 Ralf Bauer,1 Matthias Aurich,1 Sebastian J Buss,1 Henning Steen,1 Klaus Altland,2 Hugo A Katus,1 Arnt V Kristen1 1Department of Cardiology, Angiology, and Respiratory Medicine, University Hospital Heidelberg, Heidelberg, Germany; 2Institute of Human Genetics, Justus-Liebig-University, Giessen, Germany Background: Causative treatment of patients with wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is lacking. Recent reports indicate the potential use of epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, to inhibit amyloid fibril formation. We sought to investigate changes of cardiac function and morphology in patients with wtATTR-CM after consumption of green tea extract (GTE). Methods: Twenty-five male patients (71 [64; 80] years) with wtATTR-CM were submitted to clinical examination, echocardiography, cardiac magnetic resonance imaging (cMRI) (n=14), and laboratory testing before and after daily consumption of GTE capsules containing 600 mg epigallocatechin-3-gallate for at least 12 months. Results: A significant decrease of left ventricular (LV) myocardial mass by 6% (196 [100; 247] vs 180 [85; 237] g; P=0.03) by cMRI and total cholesterol by 8.4% (191 [118; 267] vs 173 [106; 287] mg/dL; P=0.006) was observed after a 1-year period of GTE consumption. LV ejection fraction by cMRI (53% [33%; 69%] vs 54% [28%; 71%]; P=0.75), LV wall thickness (17 [13; 21] vs 18 [14; 25] mm; P=0.1), and mitral annular plane systolic excursion (10 [5; 23] vs 8 [4; 13] mm; P=0.3) by echocardiography remained unchanged. Conclusion: This study supports LV mass stabilization in patients with wtATTR-CM consuming GTE potentially indicating amyloid fibril reduction. Keywords: wild-type ATTR, cardiomyopathy, polyphenol, EGCG
topic wildtype-ATTR
cardiomyopathy
polyphenol
EGCG
url https://www.dovepress.com/green-tea-extract-as-a-treatment-for-patients-with-wild-type-transthyr-peer-reviewed-article-DDDT
work_keys_str_mv AT ausdemsiepenf greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy
AT bauerr greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy
AT aurichm greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy
AT busssj greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy
AT steenh greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy
AT altl greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy
AT k greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy
AT katusha greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy
AT kristenav greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy
_version_ 1725486079361941504